Polymyxin B Sulfate Market

The Polymyxin B Sulfate market is expected to grow at a CAGR of 5.7% from 2025 to 2035. Polymyxin B Sulfate is a critical antibiotic used for treating multidrug-resistant Gram-negative infections, especially in serious conditions such as sepsis and meningitis. Its resurgence in clinical settings is largely driven by the increase in antibiotic resistance worldwide, where limited alternatives necessitate the use of older yet effective drugs like polymyxins. Rising hospital-acquired infections (HAIs) and greater focus on antimicrobial stewardship programs globally are supporting the consistent demand for high-quality Polymyxin B Sulfate.

Geographically, North America leads the Polymyxin B Sulfate market, primarily due to a high burden of antibiotic-resistant infections and robust healthcare infrastructure. Europe follows closely, where regulatory emphasis on antimicrobial resistance management is driving hospital use of last-line antibiotics like Polymyxin B. Asia-Pacific is a rapidly growing region with rising incidences of multidrug-resistant infections, particularly in countries like India and China. Expansion of hospital and critical care infrastructure and increasing government efforts to combat antimicrobial resistance are supporting market expansion in the region. Latin America and the Middle East & Africa are also witnessing moderate growth due to increasing awareness and healthcare spending.

The market report is evolving by steady growth fueled by the global fight against antimicrobial resistance and the critical need for effective last-resort antibiotics. Companies investing in safer formulations, combination therapies, and GMP-compliant production facilities will likely capture larger market shares. Strategic partnerships with healthcare providers and governments for infection control initiatives will also play a crucial role in sustaining demand.